Press Release

Article

Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers for 2024

Key Takeaways

  • Dana-Farber Cancer Institute has 42 researchers named in the 2024 Highly Cited Researchers list, highlighting their global influence in cancer research.
  • The list recognizes researchers whose work ranks in the top 1% by citations, underscoring their significant impact in their fields.
SHOW MORE

Dana-Farber Cancer Institute announced that 42 of its researchers have been named to the Highly Cited Researchers list of 2024.

Dana-Farber Cancer Institute Faculty Among Highly Cited Researchers | Image Credit: © Cornflakesei - stock.adobe.com

Dana-Farber Cancer Institute Faculty Among

Highly Cited Researchers | Image Credit:

© Cornflakesei - stock.adobe.com

Dana-Farber Cancer Institute is proud to announce that 42 of its researchers have been named to the Highly Cited Researchers list of 2024, released by the Institute for Scientific Information at Clarivate.

Highly Cited Researchers from Clarivate is an annual list that recognizes influential researchers in the sciences and social sciences from around the world who have demonstrated significant and broad influence in their field(s) of research. Each researcher selected has authored multiple Highly Cited Papers which rank in the top 1% by citations for their field(s) and publication year in the Web of Science over the past decade. Of the world's population of scientists and social scientists, Highly Cited Researchers are 1 in 1,000.

"It is an honor to see many of Dana-Farber's remarkable faculty named as Highly Cited Researchers," said Kevin M. Haigis, PhD, Chief Research Officer at Dana-Farber Cancer Institute. "The groundbreaking research that we conduct here in Boston benefits cancer patients around the world."

David Pendlebury, Head of Research Analysis at the Institute for Scientific Information at Clarivate said, "The Highly Cited Researchers list identifies and celebrates exceptional individual researchers at Dana-Farber Cancer Institute whose significant and broad influence in their fields translates to impact in their research community. Their pioneering innovations contribute to a healthier, more sustainable and secure world. These researchers' achievements strengthen the foundation of excellence and innovation that drives societal progress."

The data to develop the list derives from Essential Science Indicators, a component of InCites. For their 2024 analysis, Clarivate reviewed Highly Cited Papers from 20 broad fields in Essential Science Indicators. These fields are defined by journal groupings and in the case of multidisciplinary journals, such as Nature and Science, papers are individually assigned to a field based on cited reference analysis. Only article and review papers are considered.

Dana-Farber faculty included in this year's list are:

Philippe F. Armand

Mark M. Awad

Joaquim Bellmunt

Bradley E. Bernstein

James E. Bradner

Jennifer R. Brown

Myles Brown

Edward T. Chouchani

Alan D. D'Andrea

Glenn Dranoff

Benjamin L. Ebert

Eric S. Fischer

Gordon J. Freeman

Wendy S. Garrett

Todd R. Golub

Robert Haddad

W. Nicholas Haining

F. Stephen Hodi

Rafael A. Irizarry

Pasi A. Jänne

Panagiotis A. Konstantinopoulos

Heng Li

Nancy U. Lin

X. Shirley Liu

Ursula Matulonis

Jeffrey A. Meyerhardt

Matthew Meyerson

Nikhil C. Munshi

Donna Neuberg

Patrick A. Ott

David A. Reardon

Paul G. Richardson

Scott Rodig

Chris Sander

Geoffrey I. Shapiro

Bruce M. Spiegelman

Sara M. Tolaney

Eliezer M. Van Allen

Matthew G. Vander Heiden

Patrick Y. Wen

Catherine J. Wu

Kai W. Wucherpfennig

Related Videos
Elizabeth Buchbinder, MD
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Guru P. Sonpavde, MD
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Daniel DeAngelo, MD, PhD
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Marc Machaalani, MD
Kimmie Ng, MD, MPH
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School